Query String: LOPERAMIDE
Imodium advanced Loperamide Imodium a-d R-18553 Imodium a-d ez chews BDBM50105067 4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-N,N-dimethyl-2,2-diphenyl-butyramide; compound with methane CHEMBL1707 Imodium LOPERAMIDE HYDROCHLORIDE
med.21724, Compound 184 4-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)-N,N-dimethyl-2,2-diphenylbutanamide 4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-N,N-dimethyl-2,2-diphenyl-butyramide BDBM50017698 CHEMBL841 LOPERAMIDE Imodium LOPERAMIDE HYDROCHLORIDE 4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-N,N-dimethyl-2,2-diphenyl-butyramide(loperamide) cid_71420
- Gong, XW; Mai, JH; Xu, YH Discovery of loperamide as an antagonist of angiopoietin1 and angiopoietin2 by virtual screening. Bioorg Med Chem Lett 22: 2388-92 (2012)
- Wandel, C; Kim, R; Wood, M; Wood, A Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 96: 913-20 (2002)
- Lazarova, N; Zoghbi, SS; Hong, J; Seneca, N; Tuan, E; Gladding, RL; Liow, JS; Taku, A; Innis, RB; Pike, VW Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. J Med Chem 51: 6034-43 (2008)
- ChEMBL_333516 (CHEMBL866455) Inhibition of loperamide-stimulated [35S]GTPgammaS binding to membranes containing mu opioid receptor
- ChEMBL_333516 (CHEMBL866455) Inhibition of loperamide-stimulated [35S]GTP-gamma-S binding to membranes containing mu opioid receptor
- ChEMBL_422422 (CHEMBL909298) Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells
- ChEBML_148068 Concentration required to inhibit agonist (loperamide) stimulated [35S]GTP-gamma-S, binding to membranes containing the cloned human mu opioid receptor
- ChEMBL_148068 (CHEMBL754686) Concentration required to inhibit agonist (loperamide) stimulated [35S]GTP-gamma-S, binding to membranes containing the cloned human mu opioid receptor
- ChEMBL_422448 (CHEMBL854837) Antagonist activity against human cloned kappa opioid receptor expressed in CHO cells assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding
- ChEMBL_523527 (CHEMBL1000649) Antagonist activity at human cloned mu opioid receptor assessed as inhibition of 100 nM loperamide-stimulated GTPgammaS binding by cell based assay
- ChEMBL_422443 (CHEMBL909317) Antagonist activity against human cloned mu opioid receptor expressed in CHO cells assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding
- ChEMBL_422449 (CHEMBL854838) Antagonist activity against human cloned delta opioid receptor expressed in CHO cells assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding
- In Vitro ATPase Assay To assess the inhibition of the P-glycoprotein (Pgp/MDR1) transporter, an in vitro ATPase assay from Cyprotex was used. MDR1MDCK cells obtained from the NIH (Rockville, Md., USA) were used. Following culture, the monolayers were prepared by rinsing both basolateral and apical surfaces twice with buffer at pH 7.4 and 37 C. Cells were then incubated with pH 7.4 buffer in both apical and basolateral compartments for 40 min at 37 C. and 5% CO2 with a relative humidity of 95% to stabilise physiological parameters. For the apical to basolateral study (A-B), buffer at pH 7.4 was removed from the apical compartment and replaced with loperamide dosing solutions before being placed in the companion plates. The solutions were prepared by diluting loperamide in DMSO with buffer to give a final loperamide concentration of 5 uM (final DMSO concentration adjusted to 1%). The fluorescent integrity marker Lucifer yellow was also included in the dosing solution.